Do Bisphosphonates Alleviate Pain in Children? A Systematic Review

• Published in: Current osteoporosis reports 2020-10, Vol.18 (5), p.486-504
• Main Authors: Celin, Mercedes Rodriguez, Simon, Jackeline C., Krzak, Joseph J., Fial, Alissa V., Kruger, Karen M., Smith, Peter A., Harris, Gerald F.
• Format: Article
• Language: English
• Subjects: Bone and Joint Pain (P Mantyh and T Schnitzer; Epidemiology; Medicine; Medicine & Public Health; Orthopedics; Section Editors; Topical Collection on Bone and Joint Pain
• ISSN: 1544-1873; 1544-2241
• DOI: 10.1007/s11914-020-00621-3

Purpose of Review The goal of this systematic review is to analyze the effectiveness of bisphosphonates (BPs) to treat bone pain in children and adolescents who have diseases with skeletal involvement. Recent Findings We included 24 studies (2 randomized controlled trials, 3 non-randomized controlled trials, 10 non-randomized open-label uncontrolled studies, 8 retrospective studies, and 1 study with design not specified). The majority of included studies assessed pain from a unidimensional approach, with pain intensity the most frequently evaluated dimension. Only 38% of studies used validated tools; visual analogue scale was the most frequently employed. BPs were used to alleviate bone pain in a wide variety of pediatrics conditions such as osteogenesis imperfecta, secondary osteoporosis, osteonecrosis related to chemotherapy, chronic non-bacterial osteitis, idiopathic juvenile osteoporosis, unresectable benign bone tumor, and cancer-related pain. Twenty of the 24 studies reported a positive effect of BPs for alleviating pain in different pathologies, but 58% of the studies were categorized as having high risk of bias. Summary Intravenous BPs are helpful in alleviating bone pain in children and adolescents. It is advised that our results be interpreted with caution due to the heterogeneity of the doses used, duration of treatments, and types of pathologies included . In addition, this review shows the paucity of high-quality evidence in the available literature and further research is needed. Trial Registration Before the completion of this review, the protocol was registered to PROSPERO (International prospective register of systematic reviews), PROSPERO 2020 ID # CRD42020158316. Available from: https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42020158316.